TAIPEI, TAIWAN--(Marketwired - Jun 19, 2016) - According to the statistics of International Agency for Research on Cancer (IARC), cancer is among the leading cause of morbidity and mortality worldwide, with an average of 14 million new cancer cases and 8.2 million cancer-related deaths per year. In addition, the number of new cases is expected to rise by about 70% over the next 2 decades.
Today, cancer is still an unpredictable life event. Most people are unable to accurately calculate the risk of cancer, even though they have periodic cancer-related health check-ups or a CT scan every half year. Under the situation, many people are emotionally and financially unprepared for cancer when they are first informed about from the doctor.
Therefore, PoloWang Biotech Inc., a direct-to-consumer (DTC) genetic testing company, successfully developed the latest genetic screening techniques to detect clonal low level oncogenic mutations from circulating tumor DNA, (ctDNA) and intact circulating tumor cells (CTC). The patents of technological inventions have been applied for more than 10 countries, and been officially granted in Taiwan, Mainland China, and Australia. The characteristics of this technique is capable to accurately detect DNA mutations in only 10ml of whole blood and then calculate the individual risk of cancer for further cancer prevention. In addition, PoloWang Biotech Inc. earns ISO 13485:2003 Certification and produces various high-quality mutation detection kits. In order to help users to get the genetic testing more easier based on the concept of Direct-to-consumer (DTC), PoloWang Biotech Inc. developed a O2O cross-platform software (GenonFire) with three different interfaces to integrate end users, community clinics, and clinical laboratory all together into this cloud-based application.
Recently, PoloWang Biotech Inc. displayed their GenonFire cloud-based service system at Taiwan Cloud Expo of COMPUTEX TAIPEI 2016, and successfully attracted people from all walks of life through demonstrating O2O cross-platform software via mobile device, from account registration, arranging sampling site, to receiving final gene report. At this exhibition, people from over 200 companies in more than 5 different countries visited the booth. Many of them were very interested in this genetic testing system. Over 50 of them signed the Memorandum of Understanding (MOU) with PoloWang Biotech Inc. and expected to set up clinical laboratories, to be an agent of service, or to be a distributor of screening kits offering genetic testing at local market.
GenonFire, a cloud-based service system, transforms the health check-up from hospital-centered into patient-oriented on the strength of Bio-IoT technology. The gene data collected from anonymous would be analyzed and further combined with the environmental big data from different geographic area through this genetic screening system. Therefore, users who take the gene test can not only monitor their gene expression profiling but also raise healthy awareness for cancer prevention by determining the risk of cancer exposed to their neighborhood. This project aims to create a self-improved system which can help people have a healthy lifestyle, and keep their DNA stable in order to stay away from cancer.
GenonFire Cloud Genetic Screening System offers electronically services and automatically send gene reports to end users via mobile device. In addition, the gene data collected from anonymous would be analyzed and further combined with the environmental information from different geographic area to generate a GeneMap. Through this GeneMap, users are able to realize a distribution of the gene expression profiling from the various regions in the world, and further to determine if they are exposed to carcinogens in the environment.
About PoloWang Biotech Inc.
PoloWang Biotech Inc. was founded in 2014, which is major involved in cloud -based application development and dedicated in Cloud Intelligence Healthcare Project for the disease risk assessment.